Author: devcuration

Some companies chase horsepower. Mythic went hunting for wattage. On Dec 17, 2025, the Austin-born analog rebels closed a $125M Series D led by DCVC, with New Enterprise Associates, Atreides Management, Honda Motor Co., and Lockheed Martin stepping in with conviction. That pushes total capital raised north of $290M, not to flex valuation math, but to scale production of AI silicon that thinks more like a brain and less like a space heater. GPUs roar and gulp power. Mythic whispers, sips electrons, and still finishes the sentence. The roots explain the posture. Founded in 2012 as Isocline out of the…

Some companies build products. Others build infrastructure. KIFFIK Biomedical is building the molecular kind, the layer beneath the lab coat where biology actually tells the truth. On December 17, 2025, the Providence headquartered, Miami operated diagnostics company closed an oversubscribed Series A ahead of schedule, with global strategic investors leaning into a shared belief. Static blood tests belong to yesterday. Continuous molecular data is where modern medicine starts getting honest. Founded to commercialize the work of Dr. Abdeltif Essalik, whose non-invasive interstitial fluid extraction breakthrough dates back to 2009, KIFFIK Biomedical has played the long game in an industry addicted…

Some companies raise money. Others raise eyebrows. DNA Nanobots just raised $3.5M in seed capital from a prominent family office, closing a meaningful portion of its $5M seed round and securing an 18-month runway to attack the least glamorous and most important problem in gene therapy delivery. Real delivery. The kind that shows up on target, carries more than a polite payload, and does not leave the immune system looking for revenge. DNA Nanobots did not appear overnight. It came out of Ohio State University the hard way, built on more than a decade of research from Professor Carlos Castro…

Addition Therapeutics just stepped out of stealth with a clean $100M Series A, and the real story lives well below the headline. Founded in June 2021 as a UC Berkeley spinout, this South San Francisco company did not sprint to the spotlight. It stayed quiet, let the science mature, and waited until the data could hold eye contact without blinking. In a biotech market that rewards volume more than velocity, that restraint reads like confidence, not caution. The foundation starts with Kathleen Collins, Ph.D., UC Berkeley Professor and Division Head for Biochemistry, Biophysics, and Structural Biology. Her decades of work…

Imprint just pressed its name deeper into the financial ledger. A $150M Series D led by Khosla Ventures, a $1.2B valuation, and suddenly co-branded credit cards stop sounding like sleepy bank products and start sounding like leverage. Not noise. Signal. The kind that makes legacy issuers check their dashboards twice. Daragh Murphy did not arrive here by accident. Irish-born, Duke Law trained, shaped at WilmerHale, sharpened at McKinsey, then dropped into the operational blender at WeWork, Daragh Murphy walked away in 2019 with a clear allergy to slow systems and rented infrastructure. Alongside Gaurav Ahuja and Michael Pechman, both forged…

In 2020, inside Stanford’s orbit where real problems don’t stay theoretical for long, Wearlinq showed up asking a rude question. Why does cardiac monitoring still look like a wired science experiment taped to a human chest? Konrad Morzkowski, Stanford-trained engineer with Apple battle scars and a Forbes 30 Under 30 badge, linked up with Dr. Albert AJ Rogers, a clinical cardiac electrophysiologist and Stanford instructor who actually lives inside the signals clinicians rely on. The idea was simple and unforgiving. If heart disease kills 1 in 3 Americans, the tools to detect it early should not feel like a museum…

Clarity Pediatrics just secured $14.5M in Series A capital, and the name could not be cleaner. When the pediatrics system stays cloudy with 6-month waitlists, referrals that stall, and families refreshing portals at midnight, clarity is not branding, it is leverage. This round, led by Jackson Square Ventures with City Light Capital, MassMutual Catalyst Fund II, GingerBread Capital, Scrub Capital, and Operator Collective joining in, plus continued conviction from Rethink Impact, Maverick Ventures, and Homebrew, signals discipline over noise. Christina LaMontagne and Alesandro Larrazabal, M.D. did not stumble into this problem. They followed the data and the damage. Christina LaMontagne…

Pressure is funny. Too much of it and systems fail. Measure it right and decisions sharpen fast. That tension has lived inside CranioSense, Inc. for more than a decade, long before noninvasive brain pressure was something clinicians trusted outside the ICU. This company did not appear overnight. It incubated quietly inside Vivonics, Inc., grinding through defense-backed R&D while most of healthcare kept guessing instead of measuring. The formal spinout in 2023 was not a reinvention. It was a release valve. Years of U.S. Department of Defense funded research, real patients, and direct comparisons against gold standards that still involve drilling…

December 17, 2025. While half the market is still polishing decks and arguing about narratives, Arcads.ai went ahead and closed a $16M Seed. Mont Saint Aignan, France is not where people expect the future of performance video to come from, which is usually how you know it is real. Quiet places build loud outcomes. Arcads.ai was founded in Sept 2023 by Dylan Fournier and Romain Torres, repeat founders who already paid tuition in the real world. HelloFreshr proved distribution muscle early. Class Growth was built, scaled, and sold. A mobile app studio followed. The pattern stays consistent, learn where friction…

Growth equity does not show up when things are loud or sloppy. It shows up when the signal is clean, the data behaves, and the operators know exactly what business they are in. ClinTrial Research earned that signal. On Dec 17, 2025, the Research Triangle Park-based clinical site network closed a growth equity round led by Tarsadia Investments, and the timing says more than any press quote ever could. ClinTrial Research was built in 2024 with a blunt thesis. Clinical trials do not fail because the science collapses. They fail because execution bleeds out. Physicians churn, patients disappear, protocols expand,…